Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong survival. This project is supposed to establish a new treatment protocol for stage IV NSCLC with EGFR mutation.

Trial Details

NCT ID

NCT05215548

Phase

PHASE2

Sponsor

National Taiwan University Hospital

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

therapeutic thoracic surgery
Afatinib

Locations (sample)

Taipei, Taiwan|25.05306,121.52639
Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

Histologically or cytologically confirmed non-small cell lung cancer
Stage IV non-small cell lung cancer which is amenable to thoracic surgery
Patients must have one of the following:NSCLC which harbors EGFR exon 19 deletion or L858R mutation.
Eastern Cooperative Oncology Group (ECOG) performance status =\< 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →